vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Community West Bancshares (CWBC). Click either name above to swap in a different company.
Community West Bancshares is the larger business by last-quarter revenue ($38.3M vs $21.9M, roughly 1.7× Cue Biopharma, Inc.). On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 11.6%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 36.0%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Community West BancsharesCWBCEarnings & Financial Report
Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.
CUE vs CWBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $38.3M |
| Net Profit | $1.6M | — |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 40.0% |
| Net Margin | 7.2% | — |
| Revenue YoY | 1292.3% | 11.6% |
| Net Profit YoY | 116.7% | — |
| EPS (diluted) | $0.05 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $38.3M | ||
| Q3 25 | $2.1M | $37.9M | ||
| Q2 25 | $3.0M | $35.7M | ||
| Q1 25 | $421.0K | $34.8M | ||
| Q4 24 | $1.6M | $34.3M | ||
| Q3 24 | $3.3M | $31.3M | ||
| Q2 24 | $2.7M | $30.5M | ||
| Q1 24 | $1.7M | $20.7M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-7.4M | $10.9M | ||
| Q2 25 | $-8.5M | $7.8M | ||
| Q1 25 | $-12.3M | $8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.7M | $3.4M | ||
| Q2 24 | $-10.2M | $-6.3M | ||
| Q1 24 | $-12.3M | $3.7M |
| Q4 25 | 9.0% | 40.0% | ||
| Q3 25 | -353.4% | 39.8% | ||
| Q2 25 | -292.3% | 30.2% | ||
| Q1 25 | -2921.4% | 32.7% | ||
| Q4 24 | — | 31.0% | ||
| Q3 24 | -264.2% | 13.3% | ||
| Q2 24 | -390.6% | -25.9% | ||
| Q1 24 | -737.8% | 23.2% |
| Q4 25 | 7.2% | — | ||
| Q3 25 | -346.6% | 28.7% | ||
| Q2 25 | -287.1% | 22.0% | ||
| Q1 25 | -2911.4% | 23.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -259.6% | 10.8% | ||
| Q2 24 | -382.7% | -20.7% | ||
| Q1 24 | -719.1% | 17.8% |
| Q4 25 | $0.05 | $0.58 | ||
| Q3 25 | $-0.07 | $0.57 | ||
| Q2 25 | $-0.09 | $0.41 | ||
| Q1 25 | $-0.17 | $0.44 | ||
| Q4 24 | — | $0.29 | ||
| Q3 24 | $-0.17 | $0.18 | ||
| Q2 24 | $-0.20 | $-0.33 | ||
| Q1 24 | $-0.25 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $119.0M |
| Total DebtLower is stronger | — | $69.5M |
| Stockholders' EquityBook value | $26.4M | $409.6M |
| Total Assets | $42.2M | $3.7B |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $119.0M | ||
| Q3 25 | $11.7M | $121.6M | ||
| Q2 25 | $27.5M | $134.4M | ||
| Q1 25 | $13.1M | $148.4M | ||
| Q4 24 | $22.5M | $120.4M | ||
| Q3 24 | $32.4M | $149.0M | ||
| Q2 24 | $30.0M | $109.7M | ||
| Q1 24 | $41.0M | $61.0M |
| Q4 25 | — | $69.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $69.9M | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $409.6M | ||
| Q3 25 | $13.2M | $397.6M | ||
| Q2 25 | $18.2M | $380.0M | ||
| Q1 25 | $6.6M | $372.2M | ||
| Q4 24 | $17.5M | $362.7M | ||
| Q3 24 | $25.4M | $363.5M | ||
| Q2 24 | $21.6M | $350.2M | ||
| Q1 24 | $30.0M | $211.7M |
| Q4 25 | $42.2M | $3.7B | ||
| Q3 25 | $31.6M | $3.6B | ||
| Q2 25 | $40.7M | $3.6B | ||
| Q1 25 | $22.3M | $3.6B | ||
| Q4 24 | $32.2M | $3.5B | ||
| Q3 24 | $44.8M | $3.5B | ||
| Q2 24 | $42.3M | $3.5B | ||
| Q1 24 | $54.0M | $2.4B |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $46.1M |
| Free Cash FlowOCF − Capex | — | $43.6M |
| FCF MarginFCF / Revenue | — | 113.9% |
| Capex IntensityCapex / Revenue | 0.0% | 6.6% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $46.1M | ||
| Q3 25 | $-9.0M | $13.2M | ||
| Q2 25 | $-3.4M | $11.5M | ||
| Q1 25 | $-8.2M | $11.1M | ||
| Q4 24 | $-36.3M | $22.2M | ||
| Q3 24 | $-7.5M | $7.8M | ||
| Q2 24 | $-10.0M | $5.2M | ||
| Q1 24 | $-9.8M | $4.0M |
| Q4 25 | — | $43.6M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | $-3.4M | $10.6M | ||
| Q1 25 | $-8.3M | $10.8M | ||
| Q4 24 | $-36.4M | $17.2M | ||
| Q3 24 | $-7.5M | $5.2M | ||
| Q2 24 | $-10.0M | $4.8M | ||
| Q1 24 | $-9.8M | $3.6M |
| Q4 25 | — | 113.9% | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | -116.5% | 29.6% | ||
| Q1 25 | -1976.7% | 30.9% | ||
| Q4 24 | -2309.3% | 50.0% | ||
| Q3 24 | -225.7% | 16.7% | ||
| Q2 24 | -376.2% | 15.7% | ||
| Q1 24 | -573.0% | 17.3% |
| Q4 25 | 0.0% | 6.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.9% | 2.7% | ||
| Q1 25 | 35.6% | 0.9% | ||
| Q4 24 | 4.2% | 14.7% | ||
| Q3 24 | 0.0% | 8.1% | ||
| Q2 24 | 0.4% | 1.4% | ||
| Q1 24 | 3.2% | 2.1% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | 1.21× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.29× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
CWBC
Segment breakdown not available.
